# Betterway Medtech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/betterway-medtech

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.betterwaymed.com/
- Total disclosed funding: $15M
- Latest round: Series B (Mar 16, 2026)
- Investors on record: 2

## About

Betterway Medtech, based in Shenzhen, China, specializes in developing and manufacturing advanced medical devices focused on heart failure and vascular interventions, enhancing patient care through innovative technology.Founded in 2021, Shenzhen Betterway Medical Technology Co., Ltd. develops high-tech medical devices. The company has not undergone significant pivots and operates independently. Its headquarters are located in Shenzhen, China. Betterway Medtech's Series B funding round raised CNY 100 million on March 16, 2026, led by Tasly Capital, with participation from Triwise Capital. This round marked the company's total funding of CNY 100 million.Shenzhen Betterway Medtech Co., Ltd. specializes in the development and manufacturing of high-tech medical devices, primarily focusing on heart failure and peripheral vascular intervention. The company's core product offerings include advanced medical devices such as vascular sheaths and mechanical detachable coils, designed to address critical medical needs in cardiovascular interventions. These products facilitate minimally invasive procedures, enhancing patient safety and recovery times. Betterway Medtech's vascular sheath was approved for market release on September 18, 2024, showcasing the company's commitment to innovation and quality in medical technology. The end-users of these products include hospitals, healthcare providers, and medical professionals across multiple geographical markets, notably in Asia and Europe, aiming to improve patient outcomes in vascular treatments.Shenzhen Betterway Medtech Co., Ltd. generates revenue primarily through direct sales of its medical devices to hospitals and medical institutions. The company's transaction structure typically involves B2B sales where healthcare facilities acquire products based on their specific needs for surgical interventions. For instance, hospitals may purchase the flagship mechanical detachable coil as part of a broader procurement strategy for vascular intervention equipment. Pricing plans are structured around individual contracts that account for product specifications and volume of purchase. Betterway Medtech's innovative approach and the recent approvals of its products further enhance its position in the market, potentially increasing transaction volumes and client engagements in the medical device sector.In March 2026, Betterway Medtech raised nearly CNY 100 million in Series B funding led by Tasly Capital, with participation from Triwise Capital. The company will use these funds for new product research and development, construction of a production base, and market expansion, accelerating its innovative product layout in the fields of peripheral vascular intervention and heart failure. Betterway Medtech plans to introduce additional products targeting the cardiovascular market by 2025 and expand its reach into new markets in Europe and North America by 2026.

## Funding rounds

- Series B, Mar 16, 2026, $15M — Triwise Capital, Tasly Capital

## Investors

- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Series B
- Tasly Capital — Series B